- Oxelumab
-
Oxelumab ? Monoclonal antibody Type Whole antibody Source Human Target OX-40 ligand Clinical data Pregnancy cat. ? Legal status ? Identifiers CAS number 1186098-83-8 ATC code None Chemical data Formula C6424H9920N1704O2014S42 Mol. mass 144.6 kDa (what is this?) (verify) Oxelumab is a human monoclonal antibody designed for the treatment of asthma.[1]
Oxelumab was developed by Genentech and co-developed by Roche.
References
- ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Oxelumab". American Medical Association. http://www.ama-assn.org/resources/doc/usan/oxelumab.pdf.
Monoclonal antibodies for the immune system Immune system ("-l(i[m])-") Interleukin ("-k(i[n])-") Human ("-kinu-")Briakinumab • Canakinumab • Fezakinumab • Secukinumab • Sirukumab • Tralokinumab • UstekinumabHumanized ("-kizu-", "-kinzu-")Anrukinzumab • Enokizumab • Gevokizumab • Ixekizumab • Lebrikizumab • OlokizumabInflammatory lesions ("-les-") Mouse ("-leso-")This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it. This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.